UKUK

Creation of “Cybrids” greenlighted

17.10.2007

London – British scientists could create the country’s first interspecies embryos by the end of the year, after the Government’s fertility watchdog approved the work in principle. Two teams seeking to fuse human DNA with empty cow eggs to study diseases such as Alzheimer’s and Parkinson’s are expected to be granted licences in November, now that the Human Fertilisation and Embryology Authority (HFEA) has agreed to look favourably on their applications. The work to make cytoplasmic hybrid or “cybrid” embryos, which are 99.9 per cent human in genetic terms, should then begin immediately at King’s College London and the University of Newcastle upon Tyne, unless it is blocked by a legal challenge.
The positive verdict follows a public consultation, which in early September reported 61 per cent approval for the creation of cybrid embryos to improve scientific understanding of diseases. The research, however, is still opposed by some religious and antigenetic engineering groups, who are likely to challenge the HFEA’s legal authority to approve it. Stephen Minger, director of the Stem Cell Biology Laboratory at King’s, who leads one of the teams, said: “It is gratifying to see that the HFEA has listened to the broader scientific and bioethical community.” The ruling comes as scientists await the Government’s latest plans for legislation on interspecies embryos. Ministers have already backed down from a proposal to ban them altogether after pressure from scientists, and the draft Human Tissue and Embryos Bill to be included in the Queen’s Speech exempts cybrids while outlawing true hybrids. This, however, was condemned as excessive in July by a scrutiny committee of MPs and peers, which recommended allowing all such research subject to licensing by the HFEA.

UKUK

02.04.2012

London - The not-for-profit UK Biobank, the most comprehensive health study in Britain, is now accessible to researchers from industry and academia. The resource, which contains some 1,000 pieces of health and lifestyle...

UKUK

21.03.2012

London – The British Wellcome Trust announced on 20 March that it will launch a £200m business to invest directly in healthcare and life sciences companies. The business, up to now running under its working title Project Sigma,...

UKUK

07.03.2012

Nanopore sequencer Oxford Nanopore Technologies, a UK firm that promises its third-generation technology could theoretically sequence a human genome in 15 minutes, impressed scientists with the first public presentation of its...

UKUK

06.03.2012

GlaxoSmithKline (GSK) is further strengthening its activity in the area of rare diseases. The London-based pharma giant has signed an early-stage deal to develop and commercialise treatments for lysosomal storage disorders...

UKUK

27.02.2012

London/Montreal - Angiochem will collaborate with British pharma trust GlaxoSmithKline (GSK) plc on treatments for lysosomal storage diseases (LSD). London-based GSK will pay $300m, including up to $31.5m in upfront cash and...

UKUK

08.02.2012

London - GlaxoSmithKline re-adjusts its €3.7bn R&D budget. Following a review, three of 38 R&D units will be cut and four new ones installed, the UK drug company said in a statement on 7 Februray. Furthermore, six of the...

UKUK

03.02.2012

London - AstraZeneca tries to shed some weight, anticipating a tough year ahead. 7,300 jobs will be gone soon, the Anglo-Swedish drug company said in a statement. Research and development operations will be cancelled in...

UKUK

16.01.2012

Newhouse – An example of Schumpeter's dictum of creative destruction can be witnessed in Scotland. A former research site of US-pharma company Merck will be reborn as a biotech science park. BioCity Scotland Ltd, a joint venture...

Displaying results 1 to 10 out of 396

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-uk/article/creation-of-cybrids-greenlighted.html

Print Magazine

Event Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • 4SC0.97 EUR0.00%
  • ACTELION112.40 CHF0.00%
  • ADDEX3.30 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC0.97 EUR0.00%
  • ACTELION112.40 CHF0.00%

TOP

  • BIOFRONTERA2.90 EUR31.8%
  • VITA 344.32 EUR7.2%
  • BB BIOTECH157.70 EUR6.1%

FLOP

  • PAION2.24 EUR-27.7%
  • CYTOS0.16 CHF-23.8%
  • MAGFORCE5.90 EUR-16.9%

TOP

  • SANTHERA85.50 CHF2288.3%
  • CO.DON2.75 EUR183.5%
  • PAION2.24 EUR143.5%

FLOP

  • CYTOS0.16 CHF-95.9%
  • 4SC0.97 EUR-44.3%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 24.10.2014


Current issue

All issues

Product of the week

Products